switching arvs in virologically suppressed patients
TRANSCRIPT
Switching ARVs in Virologically Suppressed Patients
Switching ARVs in Virologically Suppressed Patients
Switching ARVs in Virologically Suppressed Patients
Switching ARVs in Virologically Suppressed Patients
Data PresentationData Presentation
AI-073: Switching Suppressed Patients to EFV/FTC/TDF
DeJesus E, et al. 48th ICAAC/46th IDSA, Washington, DC, 2008. Abst. H-1234
Phase IV, multicenter (55 US sites), open-label study (N=300)
Primary Endpoint: Non-inferiority of STR vs. SBR for HIV-1 RNA <200 c/mL
through Week 48 by TLOVR analysis
Randomization2:1
Stratify byPI or NNRTI
Continue
Switch• VL<200 c/mL
• Stable ARV Regimen • On 1st regimen or
suppressed on previous PI regimen
• No H/O VF
STR=EFV/FTC/TDF QD (n=203)
SBR=Stay on Baseline Regimen (n=97)
AI-073: Results at 48 Weeks
Virologic Failure STR 3 , SBR 1
AE’s all grades
STR: Higher incidence
-Sleep disturbance 14% vs 0
-Dizziness 11% vs 1%
-GI (nauseas, diarrhea) 6% vs 2%
DC due to AE’s STR 10 (5%), SBR 1 (1%)
GFR (CG, MDRD) No significant changes
Change TG (mg/dl) STR -20, SBR -3 (P=0.035)
Pt preference STR 91%, SBR 9% (P=0.001)
% w
ith H
IV R
NA
<50
c/m
L (T
LOVR
)
Treatment Difference (STR – SBR)95% CI:2.6% (5.9%, 11.1%)
DeJesus E, et al. 48th ICAAC/46th IDSA, Washington, DC, 2008. Abst. H-1234
ANRS 138: Enfuvirtide to Raltegravir Switch in Highly Experienced Patients
• Patients with triple-class resistance and HIV RNA <400 c/mL
• Randomized to continue ENF (n=85) or switch to RAL (n=84)
• Median of 13.6 years prior ART and 2.3 years on ENF
• Week 24 Results:• 89% <50 c/mL in both arms• Virologic Failure: 1 in each arm (∆ = 0.01%, 95% CI -4.4, +4.5)• No significant CD4 changes in either arm• Grade 3/4 AE: 11% ENF arm, 19% RAL arm (P=0.12)
• Conclusion: Raltegravir maintains suppression when substituted for ENF in fully suppressive regimens
De Castro N, et al. 16th CROI; Montreal, Canada; February 8-11, 2009. Abst. 572.
STARTMRK:RAL vs. EFV in ARV-Naïve Patients
Lennox J, et al. 48th ICAAC/46th IDSA, 2008. Abst. H-896a
RAL + TDF/FTC EFV + TDF/FTC
Me
an
Ch
an
ge
(m
g/d
L)
Weeks
Pe
rce
nt
<5
0 C
op
ies
/mL
0 2 4 8 12 16 24 32 40 48
0
20
40
60
80
100
82%
Non-inferiorityP-Value <0.001
86%
CD4 Count Increase:189 vs. 163 (p<0.05)
STARTMRK: Predictors of Success
Subgroup analyses support consistent efficacy across multiple virologic and immunologic parameters
% of Patients with HIV RNALevels <50 copies/mL
Subgroup Raltegravir Efavirenz
Overall 92% 89%
Baseline Plasma HIV RNA (c/mL) ≤50,000 95% 87%
>50,000 90% 90%
≤100,000 93% 89%
>100,000 91% 89%
Baseline CD4 Cell Counts (cells/mm3) ≤50 84% 86%
>50 to ≤200 89% 86%
>200 94% 92%
Lennox J, et al. 16th CROI; Montreal, Canada; February 8-11, 2009. Abst. 573.
D:A:D Study: PIs and Risk of MI
0.9 1 1.1 1.3 1.4
Primary model
Dyslipidemia
Elevated blood pressure
Diabetes mellitus
Lipodystrophy
Glucose
All above + lipid-lowering and antihypertensive medication
Lopinavir/r Indinavir
RR of MI (95% CI)
Effect of Adjustment for Latest Metabolic Factors
* Approximate test for heterogeneity: P=0.02
IDV NFV LPV/r SAQ #PYFU: 68,469 56,529 37,136 44,657#MI: 298 197 150 221
1.2
1.13
1
0.9
RR
/ye
ar
(95
% C
I)
Risk with Cumulative Exposure to PI
Lundgren JD, et al. 16th CROI; Montreal, Canada; February 8-11, 2009. Abst. 42LB.
SWITCHMRK 1 & 2:Study Design
• Identical, multicenter, double-blind, randomized, active-controlled studies
• Enrolled pts with HIV RNA <50 c/mL on LPV/r BID regimen in combination with at least 2 NRTIs
• No limit on number of prior ART regimens
• Prior virologic failure not an exclusion
• No lipid lowering therapy for at least 12 weeks
• Randomized (1:1) to continue LPV/r or switch to RAL
Eron J, et al. 16th CROI, Montreal, Canada, 2009. Abst. 70aLB.
SWITCHMRK 1 SWITCHMRK 2
RAL
(N=174)
LPV/r
(N=174)
RAL
(N=176)
LPV/r
(N=178)
HIV RNA
≤ 50 c/mL94.3% 92.5% 96.0% 95.5%
Mean CD4 (cells/mm3)
478 508 471 482
LPV/r ≤ 1 yr 16.7% 17.8% 17.6% 18.5%
Median yrs prior ART(min, max)
3.3
(0.3, 22.3)3.6
(0.5, 20.2) 3.7
(0.5,19.2)4.6
(0.6,16.3)
Median # prior ART(min, max)
5.0
(4.0, 16.0)5.0
(2.0, 5.0)5.5
(3.0,13.0)6.0
(4.0,14.0)
*Median Percent Change **Not prespecified for test
SWITCHMRK 1 and 2:Mean Change in Lipids at Week 12
Eron J, et al. 16th CROI; Montreal, Canada; February 8-11, 2009. Abst. 70aLB.
FastingCholesterol
NonHDL-C
FastingTriglycerides*
Fasting LDL-C
FastingHDL-C
2%1% 2%
-15%
-2%4%
-41%
1%-1%
-13%
P<0.001P<0.001
P<0.001
P=0.704 nps**
RAL + ARTsLPV/r + ARTs
-50
-40
-30
-20
-10
0
10
20
1%1% 3%
-15%
4%8%
-43%
-3%-1%
-12%
P<0.001P<0.001
P<0.001
P=0.269 nps**
FastingCholesterol
NonHDL-C
FastingTriglycerides*
Fasting LDL-C
FastingHDL-C
Cha
nge
from
bas
elin
e at
wee
k 12
, m
ean%
SWITCHMRK 1 SWITCHMRK 2
• RAL not non-inferior to maintaining LPV/r
• Further Analysis underway to assess affect of Tx experience on results• 84% with confirmed HIV RNA >50 c/mL) in the RAL group were not on
1st ART regimen; 66% with history of VF on prior regimen(s)
SWITCHMRK 1 and 2:Virologic Outcomes (NC = F)
Eron J, et al. 16th CROI, Montreal, Canada, 2009. Abst. 70aLB.
Per
cent
H
IV R
NA
<50
Cop
ies/
mL
50
60
70
80
90
100SWITCHMRK 1
0 4 8 12 24Weeks
81%
87%
(95% CI) : -6.6 (-14.4, 1.2)
0 4 8 12 24Weeks
94%
88%
(95% CI) : -5.8 (-12.2, 0.2)
SWITCHMRK 1 & 2: Resistance Summary at Time of Failure
Study DrugVirologic Failures
(>400 c/mL) Study drug mutations RTI mutations
RAL12
N155H K103N
None V118I, M184V; V179D
None V179E
G140G/S, Q148R, Q148Q/H, N155N/H D67D/G, M184V, T215T/I; Y181C
N155H M184M/V; K103R
N155H, Q148Q/R, Y143Y/C D67D/N, K70K/R, M184V, K219Q
Q148H, G140S M184V; K103N, P225H
G140G/S, Q148R, Q148Q/H, N155N/H, Q148Q/R None
N155H None
Y143Y/S, Q148Q/R None
None None
Not done Not done
LPV/r4
L10I/V, G16G/E, L63S, A71A/T, V77I None
Not done Not done
L10I, K20R, M36I, M46L, I54V, L63P, A71V, V82A, L90M K65R, D67N, K219E; K103R, Y181C
V11V/I, L63P, V77I None
Eron J, et al. 16th CROI; Montreal, Canada; February 8-11, 2009. Abst. 70aLB.
Switching ARVs in Virologically Suppressed Patients
Switching ARVs in Virologically Suppressed Patients
Debate/DiscussionDebate/Discussion